New drug for Pf malaria

July 07, 2011 12:07 pm | Updated November 02, 2016 10:58 am IST - VIJAYAWADA:

At the malaria laboratory.   Photo: R.Ragu

At the malaria laboratory. Photo: R.Ragu

With the onset of resistance to most of anti-malarial drugs, the Government in its national drug policy on malaria 2010 has recommended Artemisinin-based Combination Therapy (ACT) treatment of plasmodium falciparum (Pf) malaria.

The District Malaria Office has received Artesunate drugs to treat the patients with the ACT.

The malaria officials here also received kits to conduct rapid Pf tests. These kits would be useful at places where microscope was not available. The kits were being used to conduct tests at door steps of patients if required, according to District Malaria Officer A. Rambabu.

The drug policy has recommended that the patients suffering from Pf malaria be treated with the ACT. Artesunate drug was supplied last year, but Government has intensified the use of the new drug.

The artesunate tablets costing Rs.190 were being provided free of cost to the patients. The medicines, however, would not be given to patients across the counter.

The MPHS staff would visit the patients' houses every day to give the medicines. As part of the ACT, artesunate would be given for three days, and sulphadoxine-phyrimethamine and primaquine each on single day.

The dosage depends on various factors like age and body weight, he said.

Many physicians were unaware of the new drug and relying on old anti-malarials though resistance to anti-malarials has been reported in both Pf and Pv malaria. The drug resistance in Pf is not confined to chloroquine alone. The drug policy says that the Artesunate, Artemether and Arteether were the most effective anti-malarials.

These were used for the treatment of severe malaria and have shown very rapid parasite clearance, he explained.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.